Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
darTreg Therapy in Liver Transplantation
NCT02188719Phase 1Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2014
- Primary completion
- Jun 2019
- Modality
- Regulatory T Cells (Tregs), Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label trial of darTreg in Liver transplant rejection, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Percent of Participants With Biopsy-Proven Acute and/or Chronic Rejection at 40 weeks, Percent of Participants With Grade 3 or Higher Infectious Adverse Event(s) at 40 weeks and 3 more. Started Dec 2014; status: terminated.
02
Drugs
darTreg
03
Conditions
Liver transplant rejection
Beyond the preview
Go deeper on NCT02188719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02188719.